{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-021514","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.295635+00:00","generated_at":"2026-05-23T00:10:47.250477+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M","bullets":["Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.","IBSRELA net product sales $44.4M (+57% YoY); FY2025 guidance reaffirmed at $240–250M.","XPHOZAH net product sales $23.4M (+30% ex-returns reserve); $5.0M milestone from Fosun for China tenapanor approval.","Cash $214.0M (Dec 2024: $250.1M); SG&A $83.2M, R&D $14.9M.","Appointed Merdad Parsey to Board and Laura Williams as Chief Patient Officer in April 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-021514","json":"https://secwatch.observer/filing/0001628280-25-021514.json","markdown":"https://secwatch.observer/filing/0001628280-25-021514.md","text":"https://secwatch.observer/filing/0001628280-25-021514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/0001628280-25-021514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025021514/ardx-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:10:47.250477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}